- Breaking News 2010 Home Calendar
- Breaking News Data: Oakland crime down 10 percent in 2009
- Breaking News Miss Manners: Would you care for a dance? No, not you
- Breaking News More chickens might come home to roost in Brentwood
Alterian enters Independent Research Firm's Enterprise Marketing Platform Report as strong performer; Alterian's Enterprise Marketing Platform receives highest score in Corporate Strategy, Cost, Installed Base and Partnerships.
0 Comments | M2 Presswire, January, 2008
M2 PRESSWIRE-22 January 2008-Alterian: Alterian enters Independent Research Firm's Enterprise Marketing Platform Report as strong performer; Alterian's Enterprise Marketing Platform receives highest score in Corporate Strategy, Cost, Installed Base and Partnerships(C)1994-2008 M2 COMMUNICATIONS LTD
RDATE:22012008
Bristol, UK -- Alterian (LSE:ALN), a leading global enterprise marketing platform provider, announced today that it was among the eight companies that qualified to participate in the January 2008 Forrester Wave: Enterprise Marketing Platforms, Q1 2008. As a new entrant to this report, Alterian was cited as a strong performer.
The market will continue to grow, as evidenced by Forrester's August 2007 report "Forecast: Global...
- Getting to the root of beautiful hair: shiny, silky hair begins with a healthy scalp - includes list of resources and a recipe for an herbal scalp tonic
- Industry Experts Launch Money Management Resources to Help People Overcome Debt and Learn Proper Money Management Practices
- Portfolio forecasting tools: what you need to know
- Made from scratch: When Honda built a plant in Alabama it also built a workforce-using local workers who had no experience in making cars - Recruitment & Hiring
- Banking technology, technological learning and competition: comparative case studies in Thai banking
- John Seely Brown Inducted Into 2004 Industry Hall of Fame
- SmartDisk's New VST Flash Media Reader(TM) Reads SmartMedia(TM), CompactFlash(TM) From A Single Desktop Unit
- FDA Approves REMICADE(R) for Ninth Indication: Psoriatic Arthritis